Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial

BACKGROUND: Leptomeningeal metastasis (LM) is associated with poor prognosis in non‐small cell lung cancer (NSCLC). The aim of this study was to investigate the efficacy and safety of osimertinib combined with bevacizumab for LM from epidermal growth factor receptor mutation (EGFRm) NSCLC. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Zhi‐qin, Cai, Jing, Wang, Xia, Wei, Jian‐ping, Zeng, Zhi‐min, Huang, Long, Liu, An‐wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812067/
https://www.ncbi.nlm.nih.gov/pubmed/33205587
http://dx.doi.org/10.1111/1759-7714.13738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812067/
https://www.ncbi.nlm.nih.gov/pubmed/33205587
http://dx.doi.org/10.1111/1759-7714.13738

Ejemplares similares